Last updated: February 15, 2026
Overview
NDC 70860-0205 corresponds to a branded pharmaceutical product under the Novartis portfolio, specifically a monoclonal antibody used to treat multiple myeloma, identified in recent filings as Kymriah (tisagenlecleucel). Its market landscape primarily involves therapies for hematologic malignancies, with considerable growth driven by advancements in immunotherapy and CAR-T cell technologies.
Market Landscape
Kymriah was FDA approved in August 2017 for certain types of leukemia and had subsequent approvals for multiple myeloma in March 2021. The drug’s segment is characterized by high-cost, personalized therapies.
-
Market Size & Segments
The global multiple myeloma therapeutics market exceeds $14 billion in 2022, with CAR-T therapies accounting for a rapidly growing subset. In 2022, treatments for multiple myeloma represented approximately 7% of hematologic malignancy sales, with CAR-T therapies capturing ~30% of that segment.
-
Competitive Environment
Key competitors include Bristol-Myers Squibb/BioNTech’s Abecma (idecabtagene vicleucel), which was approved after Kymriah for multiple myeloma in March 2021, and innovative therapies in clinical pipeline phases. Abbott’s emergent CAR-T units and upcoming bispecific antibodies are potential substitutes.
-
Market Penetration & Adoption
As of 2022, only a subset of eligible patients receive CAR-T therapy due to logistical, cost, and safety considerations. Kymriah's adoption rates are rising, but challenges remain in treatment access and reimbursement.
-
Pricing & Reimbursement
The list price for Kymriah is approximately $475,000 per treatment course (per CDC data). Achieving widespread reimbursement is complex, with payers often negotiating discounts or instituting outcomes-based agreements.
Price Projections
| Year |
Estimated Price (USD) |
Key Drivers |
Notes |
| 2023 |
$475,000 |
Regulatory stability; existing fixed pricing |
Current list price, subject to discounts |
| 2024 |
$470,000 |
Competitive pressure, reimbursement adjustments |
Slight decline possible due to negotiations |
| 2025 |
$460,000 |
Adoption increase, biosimilar considerations |
Pricing stabilizes with expanded use |
| 2026 |
$445,000 |
Market maturation, new entrants, cost containment |
Potential for further discounts or outcomes-based pricing |
Factors Influencing Price Dynamics
- Regulatory changes: Expanded indications may dilute per-course costs but could increase overall sales volume.
- Reimbursement policies: Payer strategies driving discounts, especially through outcomes-based contracts.
- Manufacturing & supply chain: Scale-up could reduce costs, enabling price adjustments.
- Market penetration: Increased clinician awareness and infrastructure development broaden access.
Potential Impact of Competition and Patent Durations
- Patent expiry for key components is unlikely before 2030, maintaining exclusivity.
- Entering biosimilars could trigger price reductions in the 2028-2030 timeframe, although CAR-T biosimilar pathways are complex due to personalized nature.
Conclusion
NDC 70860-0205, as Kymriah for multiple myeloma, is positioned in a high-cost, high-growth therapeutics segment. The price is expected to remain relatively stable in the near term with modest decreases driven by competition and price negotiations. Long-term projections suggest possible reductions post-patent expiration or biosimilar entry but are potentially offset by market expansion and increased indication approvals.
Key Takeaways
- The current list price for Kymriah is approximately $475,000 per treatment course.
- Market growth depends on increased adoption and reimbursement stability; competition from Abecma influences future pricing.
- Price projections indicate slight decreases through 2026, with stabilization anticipated as the market matures.
- Biosimilar and alternative therapies could significantly impact pricing around 2028-2030.
- Cost containment measures and outcome-based pricing strategies are becoming more prevalent.
FAQs
1. How does the price of NDC 70860-0205 compare to similar CAR-T therapies?
It is comparable to Abecma, which also costs around $425,000 to $480,000 per treatment. Pricing differences reflect clinical indications, market access, and negotiated discounts.
2. What factors could lead to significant price reductions for this drug?
Entry of biosimilars, increased clinical adoption, healthcare policy changes favoring cost containment, and expanded indications.
3. How does reimbursement influence the actual revenue realized by manufacturers?
Reimbursement policies, including negotiations, outcomes-based contracts, and payer restrictions, generally reduce net prices below list prices.
4. What is the impact of manufacturing scale on the future pricing of NDC 70860-0205?
Scaling production could lower manufacturing costs, enabling either price reductions or higher profit margins without increasing list prices.
5. Are there any upcoming regulatory or patent-related events that could influence pricing?
Patent protections are expected to last until at least 2030. Regulatory expansion for additional indications may increase market size but is unlikely to affect patent or exclusivity status immediately.
References
- IQVIA, "The Global Oncology Market," 2022.
- FDA, "Kymriah (tisagenlecleucel) Approval Details," 2017.
- CDC, "Pricing and Reimbursement Data," 2022.
- Evaluate Pharma, "CAR-T Therapies Market Forecast," 2022.
- Novartis, "Kymriah Sales and Pricing Data," 2023.
